EMA Authorised: Bosulif (bosutinib (as monohydrate)) — Pfizer Europe MA EEIG

View source ↗

Summary

The European Medicines Agency authorised Bosulif (bosutinib) for treatment of chronic myeloid leukemia in the European Union, with Pfizer Europe MA EEIG as the …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Chronic Myeloid Leukemia

Drugs mentioned

• BOSULIF (bosutinib)

Snippet

Status: Authorised. Therapeutic area: Leukemia, Myeloid. MAH: Pfizer Europe MA EEIG. Decision date: 11/01/2026